In the latest session, Seres Therapeutics Inc (NASDAQ: MCRB) closed at $0.65 down -4.03% from its previous closing price of $0.68. On the day, 4119917 shares were traded.
Ratios:
For a deeper understanding of Seres Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.48 and its Current Ratio is at 1.78.
On April 21, 2023, JP Morgan started tracking the stock assigning a Neutral rating and target price of $7.
Goldman Downgraded its Neutral to Sell on July 23, 2021, whereas the target price for the stock was revised from $24 to $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 16 ’24 when Shaff Eric D. sold 11,549 shares for $1.08 per share. The transaction valued at 12,473 led to the insider holds 135,321 shares of the business.
Ege David S. sold 5,010 shares of MCRB for $5,411 on Feb 16 ’24. The insider now owns 73,856 shares after completing the transaction at $1.08 per share. On Feb 16 ’24, another insider, von Moltke Lisa, who serves as the insider of the company, sold 4,400 shares for $1.08 each. As a result, the insider received 4,752 and left with 16,988 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.78.
Stock Price History:
Over the past 52 weeks, MCRB has reached a high of $6.87, while it has fallen to a 52-week low of $0.66.
Shares Statistics:
A total of 135.04M shares are outstanding, with a floating share count of 119.44M. Insiders hold about 20.91% of the company’s shares, while institutions hold 44.23% stake in the company.
Earnings Estimates
There are Vanguard Core Bond ETF different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $70.56, with high estimates of $34.47 and low estimates of $0.65.
Analysts are recommending an EPS of between $Financial Services and $Healthcare for the fiscal current year, implying an average EPS of $Consumer Cyclical.
